Registry for Longitudinal Mortality and Therapy in Patients With Heart Failure (GREARTWAL)

August 14, 2020 updated by: Ya-Wei Xu, Shanghai 10th People's Hospital

Registry for Longitudinal Mortality and Therapy in Patients With Heart Failure (GREARTWAL Study)

The purpose of this registry is to compile a large clinical database on the medical management of patients hospitalized with acute heart failure, using information collected from hospitals across China.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Registry for Longitudinal mortality and therapy in patients with Heart Failure is a large, multicenter, prospective, open-label registry of the management of patients treated in the hospital for acute heart failure in China. The objective of this study is to investigate the clinical features and prognosis of patients with heart failure, and discover the characteristics of high-risk heart failure patients, and elucidate critical factors which predict the development and outcomes of symptomatic heart failure patients.

  1. To elucidate the clinical characteristics and prognostic risks of patients with heart failure.
  2. To study the characteristics of high-risk heart failure patients and predict the key factors for the development of symptomatic heart failure patients.
  3. To elucidate the compliance of patients with heart failure and the incidence of adverse drug effects.
  4. To investigate the effect of self-management on outcomes in patients with heart failure.
  5. To elucidate critical factors associated with the development and outcomes of heart failure.
  6. To investigate hospitalization expenses for heart failure.

Study Type

Observational

Enrollment (Anticipated)

10500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Shanghai
      • Shanghai, Shanghai, China, 200072
        • Recruiting
        • Shanghai Tenth people's hospital, Tongji university

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients with heart failure

Description

Inclusion Criteria:

- 1. 18 years and older. 2. Meet the diagnostic criteria of China 2018 or JACC/AHA 2017 or ESC 2016 heart failure guidelines.

3. Agree to be tested and sign an informed consent certificate.

Exclusion Criteria:

  • 1. Age<18 years old. 2. Patients who refused to participate. 3. Patients may have a life expectancy of less than 1 years due to non- heart failure clinical conditions.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients with heart failure
patients treated in the hospital for acute heart failure in China
Other: Mortality and Rehospitalization rate
Mortality and Re-hospitalization of acute decompensated heart failure

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mortality of acute decompensated heart failure
Time Frame: 10 years
In-hospital and Annual mortality
10 years
Re-hospitalization rate
Time Frame: 10 years
Re-hospitalization of acute decompensated heart failure
10 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Shanghai 10th People's Hospital

Collaborators

First Affiliated Hospital, Sun Yat-Sen University
Nanfang Hospital of Southern Medical University
Ningbo Medical Center Lihuili Hospital
Beijing Chao Yang Hospital
The First Affiliated Hospital of Zhengzhou University
People's Hospital of Xinjiang Uygur Autonomous Region
First Hospital of China Medical University
Xuhui Central Hospital, Shanghai
Yangpu District Central Hospital Affiliated to Tongji University
Shaanxi University of Chinese Medicine

Investigators

  • Principal Investigator: Dachun Xu, PhD, Shanghai Tenthth People's Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 1, 2018

Primary Completion (ANTICIPATED)

December 31, 2020

Study Completion (ANTICIPATED)

December 31, 2027

Study Registration Dates

First Submitted

August 9, 2019

First Submitted That Met QC Criteria

August 19, 2019

First Posted (ACTUAL)

August 20, 2019

Study Record Updates

Last Update Posted (ACTUAL)

August 17, 2020

Last Update Submitted That Met QC Criteria

August 14, 2020

Last Verified

August 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • GREARTWAL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Heart Failure

Clinical Trials on Mortality and Rehospitalization rate

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe